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Summary
 
Two models have been proposed for the molecular mechanism by which the Tal1 oncogene
causes T cell acute lymphoblastic leukemia (T-ALL). The activation model suggests that Tal1
as heterodimers with the E2A transcription factor activates the expression of oncogenes. The
inhibition model postulates that Tal1 interferes with the tumor-suppressing function of E2A. In
the Jurkat T cell line, originally derived from a patient with T-ALL, Tal1 is complexed with
E2A proteins and the transcriptional activity of E2A is very low. When E2A activity was re-
stored by expressing an E2A–Tal1 fusion protein, E-T/2, the Jurkat cells underwent growth
arrest and subsequently apoptosis, thus supporting the inhibition model and suggesting that
E2A loss may contribute to leukemic progression.
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T
 
he most common genetic alteration found in human T
cell acute lymphoblastic leukemia (T-ALL)
 
1
 
 involves
the Tal1 oncogene. Through chromosomal translocation,
interstitial deletion, or other unidentified mechanisms, Tal1
is overexpressed in as much as 60% of pediatric T-ALL
cases (1–5). Tal1 is normally not expressed in T cells;
rather, expression of Tal1 can be detected in the develop-
ing hematopoietic system (6, 7). Accordingly, disruption of
the Tal1 gene results in mice completely lacking all he-
matopoietic cells, and consequently these mice die between
embryonic day 8.5 and embryonic day 10.5 of anemia (8).
Thus, in addition to its involvement in T-ALL, Tal1 plays
a crucial role in determining the blood cell lineage (8, 9).
Recent data suggest that Tal1 regulates the development of
the vascular system as well (10).
Tal1 belongs to the basic helix-loop-helix (bHLH) fam-
ily of transcription factors involved in cell determination,
differentiation, and growth (11, 12). As dimers, these pro-
teins bind to a DNA sequence termed E box (CANNTG)
that is located in the enhancers and promoters of genes reg-
ulated by bHLH proteins. This family of transcriptional
regulators has been divided into two classes based on their
dimerization potential and expression patterns (13). Class 1
bHLH members (also called E proteins), consisting of
HEB, E2-2, and the alternatively spliced products of the
E2A gene, E12 and E47, are expressed ubiquitously and
can homodimerize efficiently. Class 2 proteins have a tis-
sue-specific pattern of expression and are incapable of
forming homodimers. Instead, they bind to DNA as het-
erodimers with the class 1 proteins. As a class 2 bHLH pro-
tein, Tal1 cannot homodimerize, but it can readily form
heterodimers with the class 1 E proteins and bind to an E
box (CAGATG) (14). Endogenous heterodimers of Tal1
and E47 have been identified in both leukemic T cells and
erythroid cells (15, 16).
The oncogenic potential of Tal1 has been demonstrated
in transgenic mice (17, 18). By expressing Tal1 in T cells
using the proximal promoter of the lck (lymphoid cell ki-
nase) gene, two separate groups have reported that the re-
sulting transgenic mice develop T cell lymphomas and die
with a median survival of 210 and 350 d, respectively (17,
18). Although these experiments show that Tal1 is indeed
an oncogene, the mechanism of Tal1-mediated leukemo-
genesis remains to be determined. Specifically, is Tal1 act-
ing as a transcriptional activator and turning on growth and
tumor promoting genes? Or is the oncogenic potential of
Tal1 due to its ability to inhibit the E proteins, which are
themselves known to suppress cell growth?
Tal1–E47 heterodimers are much less potent in activat-
ing an E box reporter construct than E47 homodimers.
Thus, in the presence of Tal1, transactivation by E47 ho-
modimers is actually diminished (19–21). This inhibition
appears to be due to the incompatibility of their respective
 
1
 
Abbreviations used in this paper:
 
 bHLH, basic helix-loop-helix; BrdU, bro-
modeoxyuridine; EMSA, electrophoretic mobility shift assay; GFP, green
fluorescent protein; PI, propidium iodide; T-ALL, T cell acute lympho-
blastic leukemia; zVAD, zVAD-fluoromethylketone. 
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activation domains, since a heterodimer between E47 and a
fusion protein consisting of the NH
 
2
 
-terminal activation
domains of E47 and the bHLH domain of Tal1 is as potent
as E47 homodimers in transcriptional activation (21). Fur-
thermore, because disruption of the E2A gene renders mice
susceptible to T cell lymphomas, E2A gene products are
thought to act as tumor suppressors in mice (22, 23). It is
possible that E2A products play a role in controlling the pro-
liferation and/or survival of T cells, and loss of this activity
eventually leads to deregulated growth and tumor formation.
Therefore, oncogenesis mediated by Tal1 may be through
inhibition of the growth-regulating activity of E2A. If sup-
pression of E2A activity is important for Tal1-transformed
leukemic T cells to proliferate and survive, then restoration
of E2A function in these cells should lead to growth inhibi-
tion and decreased cell survival. Here we show that restora-
tion of E2A activity in human leukemic T cells results in a
profound inhibition of growth and an increase in apoptosis.
These data support the hypothesis that Tal1-mediated leuke-
mogenesis is through the inhibition of E2A activity.
 
Materials and Methods
 
Expression of E-T/2 in Jurkat Cells.
 
To generate the retrovi-
ral construct expressing the E-T/2 protein, a BamH1-Asp718
fragment containing the coding sequence of E-T/2 (21) was first
inserted into the green fluorescent protein (GFP)-N1 vector
(Clonetech). The resulting plasmid was digested with EcoRI, and
the insert was subcloned into the MIGR1 vector (24). The Phoe-
nix packaging cell line was grown in DMEM containing 10%
FCS. At 70% confluence, the cells were transfected with 20 
 
m
 
g of
DNA, in the presence of 25 
 
m
 
M chloroquine using the CaPO
 
4
 
precipitation method as previously described (25). The DNA
precipitates were removed 10 h later. 24 h after transfection, the
media was replaced with RPMI plus 10% FCS. Viral supernatants
were collected 24 h later, and loose cells were removed by cen-
trifugation. The supernatants were either used immediately or
were frozen on dry ice and stored at 
 
2
 
80
 
8
 
C.
Log phase Jurkat/E cells (26), S194, and PD31 were infected
with viral stocks at a density of 3 
 
3
 
 10
 
5
 
/ml in the presence of
4 
 
m
 
g/ml polybrene for 24 h. The cells were then cultured for 3 d
in RPMI containing 10% FCS (PD31 were also supplemented
with 50 
 
m
 
M 
 
b
 
-ME) and sorted using a Coulter Epics Elite sorter.
GFP-positive cells were collected in RPMI containing 20% FCS.
In some cases, the cells were sorted again to remove any contam-
inating cells (usually representing 5% of the sorted cells). The
sorted cells were incubated overnight before any analyses were
carried out.
 
Western Blot and Electrophoretic Mobility Shift Assays.
 
For West-
ern blot analyses, infected Jurkat/E cells, S194, and PD31 were
lysed in SDS sample buffer at a concentration of 3 
 
3
 
 10
 
4
 
 cells/
 
m
 
l.
Equal amounts were loaded on a 12% SDS polyacrylamide gel.
Proteins were transferred onto a nitrocellulose membrane over-
night in transfer buffer (25 mM Tris, 190 mM glycine, and 20%
methanol) at 150 mA. The membrane was blocked for at least 2 h
in 5% nonfat milk in TBST (10 mM Tris, pH
 
 
 
8.0, 150 mM
NaCl, and 0.05% Tween 20) at room temperature. Polyclonal
antibodies against E47 (Santa Cruz Biotechnology) were added to
the blocking solution at a dilution of 1:1,000 and incubated for
2 h at room temperature. Immunoreactive proteins were de-
tected by ECL (Amersham).
 
For electrophoretic mobility shift assays (EMSAs), nuclear
extracts were prepared as previously described (27). Nuclear ex-
tracts were incubated with preimmune sera, anti-E47, or anti-
Tal1 antibodies (28) for 10 min at room temperature. The bind-
ing reactions using these nuclear extracts were then carried out at
room temperature for 20 min in a buffer containing 20 mM Tris,
pH 7.5, 60 mM NaCl, 5% glycerol, 1 mM dithiothreitol, 1 mM
EDTA, 0.125 mg/ml poly dI-dC, and the 
 
32
 
P end-labeled probe
(10
 
4
 
 cpm). The binding complexes were resolved on a 5% poly-
acrylamide gel in 0.5
 
3
 
 TBE. The sequence of the oligonucle-
otide probe is as follows: 5
 
9
 
 GTGGACGCCAACCTCAACA-
GATGGTCGGCTCACGGCATAG 3
 
9
 
 (top strand).
 
Analyses for Growth and Apoptosis.
 
For growth curve analysis,
the sorted cells were resuspended in RPMI containing 1, 5, and
15% FCS at a density of 10
 
5
 
 or 5 
 
3
 
 10
 
4
 
/ml. The cells were
stained with trypan blue to exclude dead cells and counted daily
in a hemacytometer. For the clonogenicity assay, infected cells
were plated onto 96-well plates at a density of two cells per well
in RPMI containing 10% FCS. A total of 500 wells were plated
for each construct. Jurkat/E colonies were counted 51 d later,
and S194 and PD31 colonies were counted 14 d later.
For propidium iodide (PI) staining, 
 
z
 
2 
 
3
 
 10
 
4
 
 cells were spun
down and resuspended in 25 
 
m
 
l of PBS with 1% FCS. While vor-
texing, 0.2 ml of ice cold ethanol was added, and the cells were
allowed to dehydrate overnight at 4
 
8
 
C. Cells were collected by
centrifugation and resuspended in 250 
 
m
 
l of PBS containing 1%
FCS, 0.1 mg/ml RNase A, and 50 
 
m
 
g/ml PI, followed by incu-
bation at 37
 
8
 
C for 2 h. A total of 10,000 events were recorded
using FACScan
 
®
 
 and analyzed by using the Modfit LT2.0 pro-
gram (Verity Software House Inc.).
For bromodeoxyuridine (BrdU) and PI double staining, in-
fected Jurkat/E cells were sorted and labeled with 2 
 
m
 
M BrdU
for 30 min 3 d later. Cells were fixed and stained with antibodies
against BrdU conjugated to fluorescein (Boehringer Mannheim)
and PI as described by Lissy et al. (29).
 
Results and Discussion
 
Restoration of E2A Activity in Jurkat T-ALL Cells.
 
We
chose the human Jurkat T cell line as a system to study the
mechanism of Tal1-mediated oncogenesis. Jurkat is a phys-
iologically relevant cell line in that it was originally derived
from a patient with T-ALL (30) and it expresses the Tal1
protein (15). As shown in Fig. 1 C, an EMSA using a nu-
clear extract from Jurkat cells reveals both the E47 ho-
modimeric and Tal1–E47 heterodimeric complexes (lane
1). Preincubation of the nuclear extract with Tal1 antibod-
ies specifically disrupts the Tal1–E47 heterodimer (lane 2),
whereas addition of E47 antiserum abolishes both com-
plexes (lane 3). It is interesting to note that the majority of
E47 exists as heterodimers with Tal1 in Jurkat cells. Since
Tal1–E47 heterodimers have been shown to be transcrip-
tionally inactive (19–21), this result implies that only a
small portion of E47 proteins in Jurkat cells is functional in
transcriptional activation. Indeed, very little endogenous
E47 transcriptional activity is present, since transfection
into Jurkat cells of an E box reporter plasmid results in
small amounts of expression of the reporter as compared
with other cell lines (data not shown).
Because most of E47 in Jurkat cells is complexed with
Tal1 as transcriptionally inactive heterodimers, we sought 
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to restore E47 activity by expressing exogenous E47, thus
increasing the formation of E47 homodimers. If the inhibi-
tion of E47 by Tal1 is important for the proliferation and/or
survival of Jurkat cells, restoration of E47 activity should
then lead to a reduction in growth and/or decreased sur-
vival. To test this hypothesis, an E47/GFP expression plas-
mid was constructed that enabled GFP to be translated
from an internal ribosomal entry site located 3
 
9
 
 to the cod-
ing sequence of E47. Therefore, any cell that expressed
GFP was assumed to also express E47. By sorting trans-
fected cells for GFP expression, it was possible to purify the
transfected cells away from the majority of untransfected
cells. Cells transfected with the plasmid expressing E47 and
GFP or the vector expressing GFP alone, as a control, were
sorted for GFP fluorescence 24 h after transfection. The
growth rates of the transfected cells were compared 2 d
later. Control cells multiplied 3.5-fold on the average,
whereas cells expressing E47 did not expand at all. This ex-
periment demonstrates that restoration of E47 activity leads
to growth inhibition in Jurkat cells.
Although this transient transfection experiment shows
the growth suppressive effect of E47, it is difficult to rule
out that the growth inhibition is due to the exceedingly
high levels of E47 expression. Therefore, to restore E47 ac-
tivity in Jurkat cells to endogenous levels, E-T/2, an E47-
Tal1 fusion protein, was used. This protein contains the
NH
 
2
 
 terminus of E47, including the known activation do-
mains, fused to the bHLH domain and COOH terminus of
Tal1 (21). Hence, E-T/2 cannot form homodimers to bind
to DNA and activate transcription on its own. However,
when E-T/2 is cotransfected with E47 into HeLa cells, the
resulting heterodimers can activate transcription as potently
as E47 homodimers (21). More importantly, when trans-
fected alone into Jurkat cells, E-T/2 can increase the ex-
pression of a reporter construct by 13-fold. Because the
transcriptional activity of E-T/2 is limited by the amount
of endogenous E47, this 13-fold activation probably re-
flects the physiological level of E47 activity.
E-T/2 was delivered into Jurkat cells using a retroviral
vector. Due to the extremely low infection efficiency with
an amphotropic virus, a Jurkat cell line expressing the re-
ceptor for ecotropic retroviruses (Jurkat/E) was used (26).
The E-T/2 expressing construct (Fig. 1 A) or the MIGR1
parental vector as a control was transfected into the Phoe-
nix-E packaging cell line to produce ecotropic viruses with
high titers. Similar to the plasmids used in the transfection
experiment, these retroviral constructs contain the coding
sequence for GFP translated from an internal ribosomal en-
try site. Thus, it was likely that cells that expressed GFP
also expressed E-T/2. 4 d after infection, infected cells
were purified by sorting for GFP fluorescence. The bright-
est 5% of the cells were collected and allowed to recover
for 24 h before the analyses of growth properties. Expres-
sion of E-T/2 in the infected cells was confirmed by West-
ern blotting with antibodies against E47. As shown in Fig.
1 B, whole cell lysates from infected cells 7 d after infection
showed expression of the protein. E-T/2 and E47 proteins
produced by transient transfection into HeLa cells were
used as positive controls. To detect heterodimers between
E-T/2 and endogenous E47, EMSA was performed with
nuclear extracts prepared from vector- or E-T/2–infected
cells 9 d after infection (Fig. 1 C). In addition to the en-
dogenous E47/Tal1 complex, a new complex appeared in
the cells infected with E-T/2 (Fig. 1 C, compare lanes 4
and 6). Based on the fact that this complex migrates simi-
larly to E47 homodimers and can be displaced by anti-Tal1
antibodies (lane 7), we conclude that this complex represents
the heterodimer between E-T/2 and endogenous E47.
 
Growth Inhibition as a Result of E-T/2 Expression in Jurkat
Cells.
 
Growth rate analyses were set up using vector- and
E-T/2–infected cells. As shown in Fig. 2, cells infected
with E-T/2 were severely impaired in their ability to pro-
liferate when cultured in 1, 5, or 15% FCS. This impair-
ment was most pronounced at the lowest serum concentra-
tion. By day 5, cells infected with E-T/2 had started to
level off in their growth. In contrast, cells infected with the
control virus continued to proliferate. By day 7, the num-
ber of cells in the E-T/2 infection had actually decreased to
a level lower than the initial starting point. Significant inhi-
Figure 1. Expression of E-T/2
in Jurkat/E cells. (A) The E-T/2
retroviral construct. The check-
ered and hatched boxes represent
the coding sequences of E-T/2
and GFP, respectively. The tran-
script of the retroviral construct
as depicted by a thin line with an
arrowhead encodes both E-T/2
and GFP proteins, which are
shown as thick lines. (B) West-
ern blot using anti-E47 antibod-
ies. Total cell extracts were pre-
pared from Jurkat/E cells
infected with the indicated ret-
rovirus, or from HeLa cells tran-
siently transfected with the indi-
cated construct cloned in the
pcDNA3 vector. The relevant bands are marked on the side. (C) EMSA.
Nuclear extracts were prepared from Jurkat/E cells uninfected or infected
with vector or E-T/2 retrovirus. The extracts were preincubated with the
indicated antibodies before the binding reactions. The specific binding
complexes are marked on the side.
Figure 2. Reduction of the growth rate of Jurkat/E cells by E-T/2.
On day 0 (24 h after sorting), the infected cells were plated at densities of
105/ml in media containing 1% FCS and 5 3 104/ml in media containing
5 or 15% FCS. Viable cells were counted daily from day 1 to day 8 by us-
ing a hemacytometer after trypan blue exclusion of the dead cells. The
data is a representative of several experiments. 
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bition of growth was also observed in cells cultured in the
presence of 5 and 15% FCS. The doubling times for E-T/2
cells cultured under these conditions were increased by
twofold compared with control cells. To exclude the possi-
bility that the decrease in growth rate of Jurkat/E cells was
due to nonspecific toxicities of the E-T/2 protein, negative
controls were performed by using two murine B cell lines,
S194 (plasmacytoma) and PD31 (Abelson virus-trans-
formed pre-B cell). After these cells were infected with the
E-T/2 and MIGR1 viruses, they were sorted for GFP fluo-
rescence and their growth rates were monitored. As shown
in Fig. 3, expression of E-T/2 in these two cell lines did
not appear to have any effect on their growth rates.
As an alternative measure of growth properties, clonoge-
nicity of the infected cells was determined. Jurkat/E cells
infected with the control or E-T/2 virus were purified and
seeded in 500 wells at a density of two cells per well in me-
dia containing 10% FCS. In two separate experiments, 23
and 38 wells from the E-T/2–infected cells were found to
contain proliferating cells, in contrast to 242 and 245 wells for
control cells. In comparison, the clonogenicities of E-T/2
infected S194 and PD31 cells were not significantly different
from their vector-infected counterparts (131 vs. 260 for S194,
and 384 vs. 453 for PD31). These results, together with those
from the growth rate analysis, demonstrate that expression of
E-T/2 leads to inhibition of cell growth specifically in Jurkat
cells, whose growth and/or survival may depend on the
absence of E2A function. However, S194 and PD31 cells,
which are probably transformed through other mechanisms,
are insensitive to the expression of E-T/2 protein.
 
Apoptosis in Growth-arrested Jurkat Cells.
 
To examine the
cell cycle distribution of the infected cells, we stained the
cells with PI to determine their DNA content (Fig. 4 A).
The E-T/2–infected cells did not show any significant dif-
ference in their distribution of G1, S, and G2/M phases
compared with the control infected cells. However, the
presence of a sub-G1 peak in the E-T/2–infected cells, but
not the vector-infected cells, suggested that these cells were
undergoing apoptosis. This apoptotic population repre-
sented 
 
z
 
15% of the cells. To corroborate these findings,
the infected cells were stained with Hoechst 33258 to ex-
amine their nuclear morphology (Fig. 4 B). The nuclei of
control-infected cells were smooth and round. In contrast,
a fraction of the nuclei of E-T/2–infected cells appeared
twisted and fragmented, indicative of apoptosis (31).
These results raise the question of whether the growth
retardation by E-T/2 is due to a primary apoptotic event or
a cell cycle arrest that subsequently results in apoptosis. To
address this question, we used the caspase inhibitor, zVAD-
fluoromethylketone (zVAD; reference 32), to prevent apop-
tosis in E-T/2–expressing cells, and asked if the inhibitor
could increase the growth rate of these cells. As shown in
Fig. 5 A, addition of zVAD increased the growth of neither
vector- nor E-T/2–infected cells over a period of 4 d
Figure 3. No effect on the growth rate of S194 and PD31 cells by
E-T/2. (A) Growth curves. On day 0 (24 h after sorting), S194 and PD31
infected cells were plated at densities of 3 3 105 and 5 3 105 cells/ml, re-
spectively in media containing 5% FCS. Viable cells were counted daily
using a hemacytometer after trypan blue exclusion of the dead cells. The
data is representative of several experiments. (B) Western blot using anti-
E47 antibodies. Total cell extracts were prepared from S194 and PD31
cells infected with the indicated retrovirus. The E-T/2 and endogenous
E2A proteins are indicated by the arrows. A degradation product of E-T/2
in PD31 cells is marked by an asterisk.
Figure 4. Apoptosis in E-T/2 infected cells. (A) PI staining of sorted
Jurkat/E cells, which were cultured in media containing 5 or 15% FCS
for 5 d. The sub-G1 peak is marked by a thin line on the top. The per-
centage of this population of cells is indicated. (B) Hoechst 33258 staining
of the sorted Jurkat/E cells infected with the vector or E-T/2 virus and
cultured for 5 d in media containing 5% FCS. 
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(comparing cells treated with the zVAD inhibitor and with
the DMSO vehicle). To determine if zVAD can prevent
apoptosis in these cells, the vector- and E-T/2 infected
cells were stained with PI on day 4. Indeed, the apoptotic
population in E-T/2–infected cells was partially reduced by
addition of zVAD (Fig. 5 B). As a control, Jurkat/E cells
were cultured for 2 d in the absence of FCS to induce apop-
tosis. In the presence of zVAD, the apoptotic population
also decreased dramatically. If the growth retardation in
E-T/2–infected cells was due to enhanced apoptosis trig-
gered by caspases, addition of zVAD would have been able
to block the process and increase the growth rate. There-
fore, our data suggests that the growth inhibition of these
cells may not be the direct result of enhanced apoptosis
mediated through the caspases, but rather may be due to an
intrinsic poor ability of these cells to proliferate.
 
Inefficient BrdU Incorporation in E-T/2–expressing Cells.
 
To further examine the proliferative properties of E-T/2–
expressing cells, we evaluated their ability to incorporate
BrdU. 3 d after the infected cells were sorted, they were la-
beled with BrdU and then stained for both PI and BrdU.
As shown in Fig. 6, although the percentage of cells in S
phase as determined by PI staining (R1) was similar in vec-
tor- and E-T/2–infected cells, those S phase cells express-
ing E-T/2 appeared deficient in their ability to incorporate
BrdU. Within the R1 gate for cells in the S phase, the
mean staining for BrdU was 16.0 for vector infected cells,
whereas the mean was only 10.8 for E-T/2–infected cells.
Furthermore, 60% of vector-infected cells belong to the
group with brighter staining for BrdU, whereas only 31%
of E-T/2–infected cells have the same staining intensity.
Thus, this experiment suggests that one of the reasons for
the growth inhibition may be due to the inefficiency of E-T/
2–expressing cells to transit through the S phase of the cell
cycle. As a result of this aberrant delay in S phase, a fraction
of the cells may subsequently undergo apoptosis.
Taken together, our data show that expression of the
E-T/2 construct inhibits the proliferation of Jurkat cells,
which subsequently leads to apoptosis of the cells. This
growth-inhibitory effect of the E-T/2 fusion protein may
be due to the restoration of E2A transcriptional activity that
is repressed by Tal1 in Jurkat cells. E-T/2, as a heterodimer
Figure 5. Treatment of infected
Jurkat/E cells with the caspase inhib-
itor, zVAD. (A) The growth of Jur-
kat/E cells infected with the vector
or E-T/2 virus. Cells were sorted for
GFP twice and plated in media con-
taining 5% FCS without or with 1:500
vol/vol of DMSO or the same vol-
ume of zVAD (20 mM). On the in-
dicated day after plating, cells were
counted as previously described. On
day 2, an equal volume of fresh me-
dium containing the same concentra-
tion of zVAD or DMSO was added.
Data shown are representatives of
three separate experiments. (B) PI
staining. On day 4 after plating, the
cells cultured as in A were analyzed.
The percentage of apoptotic cells is
shown above the thin lines. 
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with endogenous E2A proteins, may be able to activate the
expression of E2A-controlled genes, which encode pro-
teins involved in growth suppression. We have previously
shown that E2A can stimulate transcription of the gene
coding for a cyclin-dependent kinase inhibitor, p21
 
CIP
 
, in
HeLa, 293T, and NIH3T3 cells (33). However, the p21
protein was not detectable in Jurkat T cells with or without
E-T/2 expression (data not shown). Other growth-sup-
pressing genes may be involved. The defect in BrdU incor-
poration would point to some aspect of DNA synthesis as a
possible target, which may be negatively regulated by E2A,
perhaps through indirect mechanisms. Differential screen-
ing experiments have revealed several transcriptional re-
pressors being upregulated in E-T/2–expressing cells. It re-
mains to be determined if these repressors control the
transcription of certain genes crucial for S phase function.
The function of E2A or E-T/2 proteins in suppressing
the growth of T cells is consistent with the finding that loss
of E2A function leads to the development of T cell lym-
phoma in either E2A-deficient mice (22, 23) or transgenic
mice expressing the Id1 inhibitor of E2A (Kim, D., and
X.-H. Sun, manuscript in preparation). Similarly, trans-
genic mice expressing Tal1 also develop T cell lymphoma,
albeit with a longer latency and lower incidence (17, 18).
Because Tal1 has been shown to diminish the transcrip-
tional activity of E2A proteins in transfection assays, it is
conceivable that Tal1 acts as an inhibitor of E2A in causing
T cell lymphoma. This hypothesis is supported by the fact
that transgenic mice expressing the truncated version of
Tal1 lacking the NH
 
2
 
-terminal activation domain can still
synergize with LMO1 in causing T cell malignancies (34).
The same scenario may apply to human T-ALL, where
Tal1 may also interfere with the normal function of E2A,
i.e., maintaining the balanced growth of T cells. As we
have shown using the Jurkat T-ALL cell line, restoration of
E2A function by expressing E-T/2 leads to the growth ar-
rest of Tal1-expressing cells. The ability of E-T/2 to inhibit
the growth of T-ALL cells may thus be potentially useful
for therapeutic purposes. When delivered into bone mar-
row cells of T-ALL patients through gene therapy ap-
proaches, E-T/2 may restore E2A activity to inhibit the
growth of leukemic cells.
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Figure 6. BrdU incorporation of E-T/2 infected Jurkat/E cells. In-
fected Jurkat/E cells were labeled with BrdU 3 d after sorting and stained
with anti-BrdU conjugated to both fluorescein and PI. PI staining was
first used to delineate S phase cells (gate 5 R1). These cells were then
quantitated for the intensity of BrdU staining. The data is representative
of several experiments. 
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